Health Affairs July 20, 2022
Gabriela Gracia, Frank S. David, Rena M. Conti

Following on the Lower Drug Costs Now Act (H.R.3) and the Reduced Costs and Continued Cures Act (H.R.5260), Senate Democrats have now agreed on new language seeking to rein in the prices of prescription drugs to improve access and affordability; if approved by the Senate parliamentarian, the new language would be part of a scaled-down reconciliation package dealing with health care, climate change, and other issues.

All these proposals would provide for the Secretary of Health and Human Services (HHS) to negotiate prices for select drugs on behalf of patients. The new language and H.R.3 would allow HHS to penalize companies for price increases in excess of the rate of inflation; H.R. 3 was projected by the Congressional Budget Office to save...

Today's Sponsors

Amwell
Oliver Wyman
Upfront Healthcare

Today's Sponsors

Qure4u
H1

Today's Sponsor

HealthITq

 
Topics: Biotechnology, Investments, Pharma / Biotech, Survey / Study, Trends
The American Heart Association Launches Precision Medicine Platform, New Proprietary Computational Models for Oncology Drug Discovery, More
Biotech's newest odd couple: A pharma insider and a music maven launch a health care VC
Verge Genomics’ Alice Zhang on a young biotech founder’s ‘superpower’ and going from target to drug
Sanofi exec jumps to Owkin to ramp up the AI biotech’s pharma partnership plans
Listen: Pharma’s telehealth gold mine, the return of the biotech IPO, & a merger deferred